Silence Therapeutics Plc - ADR
SLN
Get informed when a big investor buys or sells
+ FollowMarket Cap$325.91M
Close$
$0.11
98.3% downside
Current Fair Value
98.3% downsideOvervalued by 98.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $325.91 Million |
|---|---|
| Enterprise Value | $320.12 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.89 |
| Beta | 1.48 |
| Outstanding Shares | 47,234,192 |
Return
| Return on Equity | 109.47% |
|---|---|
| Return on Assets | -46.98% |
| Return on Invested Capital | -66.05% |
Valuation & Multiples
| P/E Ratio | -4.34 |
|---|---|
| PEG | 9.13 |
| Price to Sales | - |
| Price to Book Ratio | 2.14 |
| Enterprise Value to Revenue | 381.55 |
| Enterprise Value to EBIT | -3.86 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 20, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$1.25 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
$1.40 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.6667▲ 166.67% |
|---|---|
| Total Calls | 18,900▲ Infinity% |
| Total Puts | 31,500▼ 20.85% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 42.15%▼ 72.74% |
|---|---|
| Total Invested | $102.08M▼ 3.77% |
| Investors Holding | 58▼ 1.00% |
ESG Score
No data
About Silence Therapeutics Plc
74 employees
CEO: David Solomon